OCA
ALNY icon

Octagon Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Octagon Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,300
Closed -$7.47M – 35
2022
Q3 		$7.47M Buy
+37,300
New +$7.11M 1.29% 19

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Octagon Capital Advisors's ALNY Position: Q4 2022 in Review

Octagon Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 37,300 shares — an estimated $7.47M sold.

Octagon Capital Advisors first reported a position in ALNY in Q3 2022 and held it in 1 quarter. The position peaked at $7.47M in Q3 2022. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

  • Octagon Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 37,300 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $7.47M.
  • Octagon Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's Alnylam Pharmaceuticals position peaked at $7.47M in Q3 2022.
  • 487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.